107 related articles for article (PubMed ID: 8471596)
1. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide.
Gold JE; Malamud SC; LaRosa F; Seder R; Osband ME
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):213-21. PubMed ID: 8471596
[TBL] [Abstract][Full Text] [Related]
2. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.
Gold JE; Malamud SC; LaRosa F; Osband ME
Am J Hematol; 1993 Sep; 44(1):42-7. PubMed ID: 8342564
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
4. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
5. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
Gold JE; Masters TR; Osband ME
J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.
Gold JE; Ross SD; Krellenstein DJ; LaRosa F; Malamud SC; Osband ME
Eur J Cancer; 1995; 31A(5):698-708. PubMed ID: 7640041
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
[TBL] [Abstract][Full Text] [Related]
9. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
10. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Babbit B; Fine EM; Weber HN; Unger PD; Leventhal I; Zippe CD; Osband ME
Br J Urol; 1995 Jul; 76(1):115-22. PubMed ID: 7648042
[TBL] [Abstract][Full Text] [Related]
12. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.
Mossoba ME; Halverson DC; Kurlander R; Schuver BB; Carpenter A; Hansen B; Steinberg SM; Ali SA; Tageja N; Hakim FT; Gea-Banacloche J; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Khuu H; Sabatini M; Stroncek D; Levine BL; June CH; Mariotti J; Rixe O; Fojo AT; Bishop MR; Gress RE; Fowler DH
Clin Cancer Res; 2015 Oct; 21(19):4312-20. PubMed ID: 26071480
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
Curti BD; Ochoa AC; Powers GC; Kopp WC; Alvord WG; Janik JE; Gause BL; Dunn B; Kopreski MS; Fenton R; Zea A; Dansky-Ullmann C; Strobl S; Harvey L; Nelson E; Sznol M; Longo DL
J Clin Oncol; 1998 Aug; 16(8):2752-60. PubMed ID: 9704728
[TBL] [Abstract][Full Text] [Related]
15. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993; 36(4):229-36. PubMed ID: 8439986
[TBL] [Abstract][Full Text] [Related]
16. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma.
Sawczuk IS
Urol Clin North Am; 1993 May; 20(2):297-301. PubMed ID: 8493751
[TBL] [Abstract][Full Text] [Related]
17. Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions.
Kohler PC; Hank JA; Minkoff DZ; Sondel PM
Cancer Immunol Immunother; 1988; 26(1):74-82. PubMed ID: 3257904
[TBL] [Abstract][Full Text] [Related]
18. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.
Hont AB; Cruz CR; Ulrey R; O'Brien B; Stanojevic M; Datar A; Albihani S; Saunders D; Hanajiri R; Panchapakesan K; Darko S; Banerjee P; Fortiz MF; Hoq F; Lang H; Wang Y; Hanley PJ; Dome JS; Bollard CM; Meany HJ
J Clin Oncol; 2019 Sep; 37(26):2349-2359. PubMed ID: 31356143
[TBL] [Abstract][Full Text] [Related]
20. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M; Siessmann KL; Mokyr MB; Dray S
Cancer Res; 1991 Sep; 51(17):4516-22. PubMed ID: 1873795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]